Analysis of Glucagon-Like Peptide-1 Agonist Trends Within An Integrated Health System Specialty Pharmacy
According to the CDC, approximately 38 million Americans have diabetes (about 1 in 10) and approximately 90-95% of those have type 2 diabetes. GLP-1 and GLP-1/GIP agonists are now recognized as first-line treatments for type 2 diabetes due to their well-established benefits. However, challenges with adherence and persistence persist. This white paper examines how a specialty pharmacy care model — leveraging ambulatory care pharmacists and pharmacy liaisons — can significantly improve adherence while helping to keep out-of-pocket costs affordable.
KEY CONCEPTS
Type 2 diabetes and obesity are major drivers of healthcare costs.
Glucagon-like peptide-1 (GLP-1) and GLP-1/gastric inhibitory polypeptide (GIP) agonists have become first-line therapies for type 2 diabetes and the benefits of these drugs are well established. However, adherence and persistence to these medications are ongoing concerns.
A specialty pharmacy care model utilizing ambulatory care pharmacists (ACPs) and pharmacy liaisons has demonstrated benefits for adherence and keeping out-of-pocket costs affordable.
